Compare DexCom, Inc. (DXCM) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Newmont Corporation — how do they compare? DexCom, Inc. trades at $90.8 (market cap $33.79B), while Newmont Corporation trades at $118.33 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 3.7× DexCom, Inc.'s market cap, and Newmont Corporation pays a 0.89% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NEM | |
|---|---|---|
Market Cap | $33.79B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $131.95 |
52-Week Low | $54.84 | $67.38 |
Enterprise Value | $33.24B | $120.09B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Newmont (NEM) trades at $118.52, up 1.07% on the day, with strong earnings beats in recent quarters and a bullish analyst consensus. Technical indicators show mixed signals with RSI near overbought levels but moving averages supporting an uptrend. Recent news highlights resolution of a Nevada dispute with Barrick and solid Q2 2026 results, reinforcing operational stability.
Outlook remains positive with a $133 consensus price target, driven by robust cash flow and gold price strength. Risks include potential cost pressures and reliance on commodity cycles, but institutional buying and high buy ratings suggest confidence in near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
